Pfizer, BioNTech and Moderna are making combined profits of $65,000 every minute from their highly successful COVID-19 vaccines while the world's poorest countries remain largely unvaccinated, according to a new analysis.
Nov 16, 2021
2
6183
Technology that reliably kills airborne viruses inside buildings could prevent most cases of cold and flu and might have saved millions of lives during the COVID-19 pandemic, according to a Rutgers expert.
Nov 9, 2022
0
61
A COVID-19 vaccine effective against multiple variants is possible before the end of 2022, the head of US pharmaceutical giant Pfizer said Wednesday.
Apr 13, 2022
0
41
(HealthDay)—Patients with poorly controlled diabetes have improvements in hemoglobin A1c and medication adherence and fewer trips to the emergency room after receiving daily text messages, according to a study published ...
Nov 22, 2013
0
0
The World Trade Organization said Friday its member nations had again failed to agree to suspend intellectual property rights for COVID-19 vaccines, with some countries doubting a deal could be reached unless certain delegations ...
Oct 16, 2021
0
39
Over a year into global COVID-19 vaccination efforts the question of whether jab formulas ought to be freely available is still unresolved—and undersupplied countries are turning to workarounds.
Jan 17, 2022
0
19
No one disputes that the world is unfair. But no one expected a vaccine gap between the global rich and poor that was this bad, this far into the pandemic.
Jul 18, 2021
0
17
With research laboratories around the world racing to develop a coronavirus vaccine, a unique challenge has emerged: how to balance intellectual property rights with serving the public good.
May 29, 2020
0
4
Researchers have called for an experimental COVID treatment, which has shown early indications of being more effective against dominant Omicron subvariants, to be made available outside the United States.
Jul 22, 2022
0
14
The World Trade Organization faces calls led by India and South Africa to waive intellectual property rights for COVID-19 vaccines—a notion fiercely rejected by pharmaceutical giants and their host countries.
Mar 1, 2021
0
2
